Table 2.

Adverse events observed during the treatments

		Adverse eventsa (gradeb)
	Patient number	Erythema	Pain	Pruritus	Fatigue	Nausea	Fever	Total
Aex	A1	+(1-2)	0	0	0	0	0	1
	A2	+(1-2)	+(1-2)	0	0	0	0	2
	A3	0	0	+(1-2)	0	0	0	1
	A4	+(1-2)	0	0	0	0	0	1
	A5	+(1-2)	0	+(1-2)	0	0	0	2
	B1	+(1-2)	0	+(1-2)	0	0	0	2
	B2	0	+(1-2)	0	0	0	0	1
	B3	+(1-2)	0	0	0	0	0	1
	B4	+(1-2)	0	+(1-2)	0	0	0	2
	B5	+(1-2)	0	0	0	0	0	1
	C1	+(1-2)	+(1-2)	0	0	0	0	2
	C2	+(1-2)	0	+(1-2)	0	0	0	2
	C3	+(1-2)	0	+(1-2)	0	0	0	2
	C4	+(1-2)	+(1-2)	0	0	0	0	2
	C5	+(1-2)	0	+(1-2)	0	0	0	2
	D1	+(1-2)	0	+(1-2)	+(1-2)	0	0	3
	D2	+(1-2)	0	+(1-2)	0	0	0	2
	D3	+(1-2)	+(1-2)	+(1-2)	0	0	0	3
	D4	+(1-2)	+(1-2)	0	0	0	0	2
	D5	+(1-2)	+(1-2)	+(1-2)	0	0	0	3
		18	7	11	1	0	0	37c
Aex + GM-CSF	E1	+(1-2)	0	0	0	0	0	1
	E2	+(1-2)	0	0	0	0	0	1
	E3	+(1-2)	0	0	0	0	0	1
	E4	+(1-2)	0	+(1-2)	0	0	0	2
	E5	0	+(1-2)	0	0	0	0	1
	F1	+(1-2)	0	+(1-2)	0	0	0	2
	F2	+(1-2)	+(1-2)	0	0	0	0	2
	F3	+(1-2)	0	0	0	0	0	1
	F4	+(1-2)	0	+(1-2)	0	0	0	2
	F5	+(1-2)	+(1-2)	+(1-2)	0	0	0	3
	G1	+(1-2)	+(1-2)	+(1-2)	0	0	0	3
	G2	+(1-2)	0	0	+(1-2)	0	0	2
	G3	+(1-2)	0	+(1-2)	0	0	0	2
	G4	+(1-2)	+(1-2)	0	0	0	0	2
	G5	+(1-2)	0	+(1-2)	0	0	0	2
	H1	+(1-2)	+(1-2)	+(1-2)	0	0	0	3
	H2	+(1-2)	+(1-2)	0	0	0	+(1-2)	3
	H3	+(1-2)	+(1-2)	+(1-2)	0	0	0	3
	H4	+(1-2)	0	+(1-2)	0	+(1-2)	0	3
	H5	+(1-2)	0	+(1-2)	+(1-2)	0	0	3
		19	8	11	2	1	1	42d

Abbreviations: Aex, ascites-derived exosomes; GM-CSF, granulocyte-macrophage colony-stimulating factor.

^aThe adverse events were recorded from the day of the first immunization of 2 weeks after the last immunization. Toxicity was assessed throughout the study using the National Cancer Institute Common Toxicity Criteria version 2.0. cThe total adverse events in the Aex-treated groups were summarized and presented. dThe total adverse events in the Aex + GM-CSF-treated groups were summarized and presented.